Menu

EPA Stalls Release of Carcinogen Report

An investigation by Politico finds the agency has been sitting on an assessment of formaldehyde’s cancer risks for a year and a half.

Jul 9, 2018
Sukanya Charuchandra

ABOVE: The Environmental Protection Agency building in Washington, D.C.
ISTOCK, YINYANG

The Environmental Protection Agency is delaying the release of a draft assessment on formaldehyde that finds the chemical causes nasal and oral cancer and leukemia, according to Politico

The report has been ready since before President Donald Trump’s entry into the White House, yet it hasn’t been forwarded to the National Academies of Sciences for review nor been made public, reports Politico.

Politico’s investigation suggests that Environmental Protection Agency (EPA) officials have been suppressing the report to cater to the chemical industry. “At every corner, you see the agency trying to either minimize the role of science or manipulate the role of science or just ignore the work of scientists in doing the critical work to ensure that human health and the environment is protected,” Jennifer McPartland, a senior scientist with the Environmental Defense Fund, tells Politico. 

EPA denies the accusations. 

According to Vox, Democratic senators in a May letter to former EPA chief Scott Pruit say, “We have also learned that, at the same time as EPA political appointees’ requests were delaying the formaldehyde assessment’s movement through the agency review process, the American Chemistry Council (ACC) as well as interested corporation such as ExxonMobil have been pressuring EPA not to release the assessment for public comment as drafted.”

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

Preparing Cell Or Tissue Lysates For ELISA Kits

Preparing Cell Or Tissue Lysates For ELISA Kits

RayBiotech manufactures over 2,000 high fully validated, GMP-compliant ELISA kits. In this blog post we explain how to prepare cell or tissue lysates for ELISA Kits.

Norgen Biotek Achieves Illumina Propel Certification as a Service Provider for Next Generation Sequencing

Norgen Biotek Achieves Illumina Propel Certification as a Service Provider for Next Generation Sequencing

Norgen Biotek Corp., an innovative privately held Canadian biotechnology company focusing primarily on nucleic acid and protein stabilization and purification, as well as providing high quality services to the scientific community, today announced that it has become Propel-Certified through Illumina as a Next Generation Sequencing (NGS) service provider.

Slice® Safety Cutters for Lab Work

Slice® Safety Cutters for Lab Work

Slice cutting tools—which feature our patent-pending safety blades—meet many lab-specific requirements. Our scalpels and craft knives are well suited for delicate work, and our utility knives are good for general use.

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.